Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Breast 11Thoracic 2Gastrointestinal 2Head & Neck 1Gynecologic 1Genitourinary 1

Conditions

Colorectal Neoplasms 4603Pancreatic Neoplasms 2843Carcinoma, Hepatocellular 2479Stomach Neoplasms 2329Colonic Neoplasms 1790Rectal Neoplasms 1719Esophageal Neoplasms 1376Liver Neoplasms 920Neoplasms 915Breast Neoplasms 839Neoplasm Metastasis 764Carcinoma, Non-Small-Cell Lung 705Cholangiocarcinoma 587Lung Neoplasms 556Ovarian Neoplasms 535Esophageal Squamous Cell Carcinoma 513Gastrointestinal Neoplasms 495Melanoma 381Prostatic Neoplasms 373Biliary Tract Neoplasms 373Head and Neck Neoplasms 303Uterine Cervical Neoplasms 288Carcinoma, Renal Cell 284Adenocarcinoma Of Esophagus 273Squamous Cell Carcinoma of Head and Neck 264Sarcoma 263Gastrointestinal Stromal Tumors 252Endometrial Neoplasms 235Urinary Bladder Neoplasms 226Gallbladder Neoplasms 225

Interventions

trametinib 1spartalizumab 1pembrolizumab 1nazartinib 1canakinumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Ductal × Gastrointestinal × Clear all
NCT04660929 2024-12-18

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Carisma Therapeutics Inc

Phase 1 Unknown
48 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Ovarian Epithelial, Adenocarcinoma, Bile Duct Neoplasms, Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Carcinoma, Small Cell, Carcinoma, Ductal, Small Cell Lung Carcinoma, Inflammatory Breast Neoplasms

NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)

Novartis

Phase 1 Completed
283 enrolled
BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔